Jennifer R Landes1, Stephen A Moore1, Brooke R Bartley1, Hung Q Doan1,2, Peter L Rady1, Stephen K Tyring3. 1. Department of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.308, Houston, TX, 77070, USA. 2. Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Dermatology, The University of Texas Health Science Center at Houston, 6431 Fannin St., MSB Room 1.308, Houston, TX, 77070, USA. Stephen.K.Tyring@uth.tmc.edu.
Abstract
PURPOSE: Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor's efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this review seeks to summarize the recent evidence of selinexor treatment in solid tumors. METHODS: Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials. RESULTS: This review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies. CONCLUSION: Further clinical investigation of selinexor treatment for solid malignancies is warranted.
PURPOSE: Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells. While selinexor is currently FDA approved to treat multiple myeloma, compelling preclinical and early clinical studies reveal selinexor's efficacy in treating hematologic and non-hematologic malignancies, including sarcoma, gastric, bladder, prostate, breast, ovarian, skin, lung, and brain cancers. Current reviews of selinexor primarily highlight its use in hematologic malignancies; however, this review seeks to summarize the recent evidence of selinexor treatment in solid tumors. METHODS: Pertinent literature searches in PubMed and the Karyopharm Therapeutics website for selinexor and non-hematologic malignancies preclinical and clinical trials. RESULTS: This review provides evidence that selinexor is a promising agent used alone or in combination with other anticancer medications in non-hematologic malignancies. CONCLUSION: Further clinical investigation of selinexor treatment for solid malignancies is warranted.
Authors: Albiruni R Abdul Razak; Morten Mau-Soerensen; Nashat Y Gabrail; John F Gerecitano; Anthony F Shields; Thaddeus J Unger; Jean R Saint-Martin; Robert Carlson; Yosef Landesman; Dilara McCauley; Tami Rashal; Ulrik Lassen; Richard Kim; Lee-Anne Stayner; Mansoor R Mirza; Michael Kauffman; Sharon Shacham; Amit Mahipal Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Edward F Attiyeh; John M Maris; Richard Lock; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Gorlick; E Anders Kolb; Stephen T Keir; Jianrong Wu; Yosef Landesman; Sharon Shacham; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Brooke R Bartley; Rebecca A Simonette; Peter L Rady; Hung Q Doan; Stephen K Tyring Journal: Int J Dermatol Date: 2022-01-30 Impact factor: 2.736
Authors: Asfar S Azmi; Husain Yar Khan; Irfana Muqbil; Amro Aboukameel; Jasper E Neggers; Dirk Daelemans; Amit Mahipal; Gregory Dyson; Mandana Kamgar; Mohammad Najeeb Al-Hallak; Anteneh Tesfaye; Steve Kim; Vinod Shidham; Ramzi M Mohammad; Philip A Philip Journal: Clin Cancer Res Date: 2019-12-12 Impact factor: 12.531
Authors: Asfar S Azmi; Yiwei Li; Irfana Muqbil; Amro Aboukameel; William Senapedis; Erkan Baloglu; Yosef Landesman; Sharon Shacham; Michael G Kauffman; Philip A Philip; Ramzi M Mohammad Journal: Oncotarget Date: 2017-07-17
Authors: Natalia Paez Arango; Erkan Yuca; Ming Zhao; Kurt W Evans; Stephen Scott; Charissa Kim; Ana Maria Gonzalez-Angulo; Filip Janku; Naoto T Ueno; Debu Tripathy; Argun Akcakanat; Aung Naing; Funda Meric-Bernstam Journal: Breast Cancer Res Date: 2017-08-15 Impact factor: 6.466
Authors: Han Bit Baek; Alan P Lombard; Stephen J Libertini; Aleida Fernandez-Rubio; Ruth Vinall; Regina Gandour-Edwards; Rachel Nakagawa; Kathleen Vidallo; Kristine Nishida; Salma Siddiqui; Hiromi Wettersten; Yosef Landesman; Robert H Weiss; Paramita M Ghosh; Maria Mudryj Journal: Oncotarget Date: 2018-10-02